Fundamentals of Pharmacodynamics and Drug Response

Enzymes

Alternatively, drugs may work by altering the activity of an enzyme. By inhibiting or enhancing enzymatic processes, drugs can manipulate the metabolic pathways that control various physiological functions.

Inter-individual Variability in Drug Response

A critical concept in clinical practice is that no two patients respond to a drug in exactly the same way. Even when given the same dose, one patient may experience a profound therapeutic effect, while another may experience toxicity or no response at all.

This phenomenon is known as inter-individual variability. In a large population, the response to a specific dose of a drug typically follows a normal distribution (a bell curve). Some individuals are highly sensitive and require very small doses (the left side of the curve), while others are resistant and require much larger doses (the right side of the curve).

Clinical Note: Because of this variability, clinicians must constantly monitor patient responses. A dose that is "standard" for one person may be toxic for another.

Quantifying Drug Response: ED50, TD50, and LD50

To standardize how we talk about drug effectiveness and safety, pharmacologists use specific statistical measures based on population responses.

Median Effective Dose ($ED_{50}$)

The Median Effective Dose ($ED_{50}$) is the dose at which 50% of a population exhibits the desired therapeutic response. While $ED_{50}$ helps predict the dose range needed for treatment, it is not a "magic number"; a dose that is effective for the median person might be toxic for a sensitive individual or ineffective for a resistant one.

Median Toxic Dose ($TD_{50}$) and Median Lethal Dose ($LD_{50}$)

Safety is measured by looking at the doses that cause harm.

• Median Toxic Dose ($TD_{50}$): The dose at which 50% of test subjects exhibit signs of toxicity.
• Median Lethal Dose ($LD_{50}$): The dose at which 50% of test subjects are killed.

Measuring Safety: Therapeutic Index and Margin of Safety

The relationship between the dose that heals and the dose that harms determines how "safe" a drug is to use in a clinical setting.

The Therapeutic Index (TI)

The Therapeutic Index (TI) is a ratio that compares the lethal dose to the effective dose. It is calculated using the following formula:

$\text{TI} = \frac{LD_{50}}{ED_{50}}$

A drug with a large TI has a wide gap between the effective dose and the lethal dose, making it relatively safe. Conversely, a drug with a small TI has an effective dose that is very close to its toxic or lethal dose, requiring much more precise monitoring.

The Margin of Safety (MOS)

While the TI is a common ratio, the Margin of Safety (MOS) provides an even more stringent look at the extremes of the dose-response curves. It compares the dose that is lethal to only 1% of the population ($LD_1$) to the dose that produces a therapeutic effect in 99% of the population ($ED_{99}$).

$\text{MOS} = \frac{LD_{1}}{ED_{99}}$

Generally, drugs with a large Therapeutic Index will also possess a larger Margin of Safety.

Potency vs. Efficacy

When comparing two different drugs within the same class, we use two distinct terms to describe their performance: potency and efficacy.

1. Potency: This refers to the amount of drug required to produce a specific intensity of response. If Drug A requires 5mg to achieve a certain effect and Drug B requires 50mg to achieve that same effect, Drug A is more potent.
2. Efficacy: This refers to the maximum intensity of the response a drug can produce, regardless of the dose. A drug that can completely eliminate pain has higher efficacy than a drug that only reduces pain slightly, even if the latter is more potent.

The Graded Dose-Response Relationship

As you increase the dose of a drug, the intensity of the response typically changes in a predictable pattern known as a graded dose-response relationship. This relationship usually follows a sinusoidal curve with three distinct phases:

• Phase 1 (Low Dose): At very low doses, there is little change in response as the dose increases because very few receptors or enzymes are being affected.
• Phase 2 (Linear Phase): As the dose increases, more receptors or enzymes are engaged, leading to a sharp, linear increase in the intensity of the response. This is generally considered the best range for achieving a safe, therapeutic effect.
• Phase 3 (Plateau Phase): Eventually, the response levels off. This happens because the drug has bound to all available receptors/enzymes, or the physiological symptom (like a headache) has been fully alleviated. Increasing the dose further at this stage will not increase the effect.

---

Summary Table for Quick Review